GKOS vs. HALO, BLCO, OPCH, CRSP, OGN, KRYS, DOCS, BPMC, BBIO, and LNTH
Should you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include Halozyme Therapeutics (HALO), Bausch + Lomb (BLCO), Option Care Health (OPCH), CRISPR Therapeutics (CRSP), Organon & Co. (OGN), Krystal Biotech (KRYS), Doximity (DOCS), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Lantheus (LNTH). These companies are all part of the "medical" sector.
Glaukos (NYSE:GKOS) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.
Glaukos has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.
Halozyme Therapeutics has a net margin of 33.96% compared to Glaukos' net margin of -42.79%. Halozyme Therapeutics' return on equity of 248.20% beat Glaukos' return on equity.
Halozyme Therapeutics has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Halozyme Therapeutics had 11 more articles in the media than Glaukos. MarketBeat recorded 17 mentions for Halozyme Therapeutics and 6 mentions for Glaukos. Halozyme Therapeutics' average media sentiment score of 0.87 beat Glaukos' score of 0.36 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.
Halozyme Therapeutics received 81 more outperform votes than Glaukos when rated by MarketBeat users. Likewise, 69.02% of users gave Halozyme Therapeutics an outperform vote while only 64.21% of users gave Glaukos an outperform vote.
Glaukos presently has a consensus target price of $99.80, suggesting a potential upside of 0.32%. Halozyme Therapeutics has a consensus target price of $53.29, suggesting a potential upside of 38.15%. Given Halozyme Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Halozyme Therapeutics is more favorable than Glaukos.
99.0% of Glaukos shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 6.4% of Glaukos shares are held by company insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Halozyme Therapeutics beats Glaukos on 14 of the 18 factors compared between the two stocks.
Get Glaukos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
